Nat Prod Sci.  2019 Sep;25(3):208-214. 10.20307/nps.2019.25.3.208.

The Effect of Trigonella foenum-graceum L. (Fenugreek) Towards Collagen Type I Alpha 1 (COL1A1) and Collagen Type III Alpha 1 (COL3A1) on Postmenopausal Woman's Fibroblast

• Yusharyahya SN
• Bramono K
• Sutanto NR
• Kusuma I

• KMID: 2459961
• DOI: http://doi.org/10.20307/nps.2019.25.3.208

Abstract

Trigonella foenum-graceum L. (fenugreek) is a phytoestrogen, a nonsteroidal organic chemical compound from plants which has similar mechanism of action to sex hormone estradiol-17β. This study aims to assess the effectivity of fenugreek seeds extract on collagen type I alpha 1 (COL1A1) and collagen type III alpha 1 (COL3A1) which are both decreased in aging skin and become worsen after menopause. This in vitro experimental study used old human dermal fibroblast from leftover tissue of blepharoplasty on a postmenopausal woman (old HDF). As a control of the fenugreek's ability to trigger collagen production, we used fibroblast from preputium (young HDF). Subsequent to fibroblast isolation and culture, toxicity test was conducted on both old and young HDF by measuring cell viability on fenugreek extract with the concentration of 5 mg/mL to 1.2 µg/mL which will be tested on both HDF to examine COL1A1 and COL3A1 using ELISA, compared to no treatment and 5 nM estradiol. Old HDF showed a 4 times slower proliferation compared to young HDF (p<0.05). Toxicity test revealed fenugreek concentration of 0.5 - 2 µg/mL was non-toxic to both old and young HDF. The most significant fenugreek concentration to increase COL1A1 and COL3A1 secretion was 2 µg/mL (p<0.05).

Keyword

COL1A1; COL3A1; fenugreek; postmenopausal

MeSH Terms

Aging
Blepharoplasty
Cell Survival
Collagen Type I*
Collagen Type III*
Collagen*
Enzyme-Linked Immunosorbent Assay
Estradiol
Female
Fibroblasts*
Humans
In Vitro Techniques
Menopause
Phytoestrogens
Skin
Toxicity Tests
Trigonella*
Collagen
Collagen Type I
Collagen Type III
Estradiol
Phytoestrogens

Figure

• 

  Fig. 1 Proliferation of young and old fibroblasts.

• 

  Fig. 2 Doubling time of young and old fibroblasts.

• 

  Fig. 3 Fenugreek extract toxicity on old HDF.

• 

  Fig. 4 Changes in old HDF morphology after treatment.

• 

  Fig. 5 Changes in young HDF morphology after treatment.

• 

  Fig. 6 COL1A1 secretion on old HDF (A) and young HDF (B); COL3A1 secretion on old HDF (C) and young HDF (D).

Reference

1. Borg M, Brincat S, Camilleri G, Schembri-Wismayer P, Brincat M, Calleja-Agius J. Climateric. 2013; 16:514–521.

2. Draelos ZD. J Drugs Dermatol. 2018; 17:1186–1189.

3. Soules MR, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N. Fertil Steril. 2001; 75:874–878.

4. Brincat M, Versi E, Moniz CF, Magos A, de Trafford J, Studd JW. Obstet Gynecol. 1987; 70:123–127.

5. Schmidt JB, Binder M, Demschik G, Bieglmayer C, Reiner A. Int J Dermatol. 1996; 35:669–674.

6. Thornton MJ. Exp Dermatol. 2002; 11:487–502.

7. Affinito P, Palomba S, Sorrentino C, Di Carlo C, Bifulco G, Arienzo MP, Nappi C. . Maturitas. 1999; 33:239–247.

8. Varila E, Rantala I, Oikarinen A, Risteli J, Reunala T, Oksanen H, Punnonen R. Br J Obstet Gynaecol. 1995; 102:985–989.

9. Rittié L, Kang S, Voorhees JJ, Fisher GJ. Arch Dermatol. 2008; 144:1129–1140.

10. Kapuścińska A, Nowak I. Chemik. 2015; 69:154–159.

11. Malaivijitnond S. Front Med. 2012; 6:8–21.

12. Agustini K, Wiryowidagdo S, Kusmana D. Majalah Ilmu Kefarmasian. 2007; 4:26–36.

13. Stevenson S, Thornton J. Clin Interv Aging. 2007; 2:283–297.

14. Thornton MJ. Dermatoendocrinol. 2013; 5:264–270.

15. Sator PG, Schmidt JB, Rabe T, Zouboulis CC. Exp Dermatol. 2004; 13:36–40.

16. Mehrafarin A, Rezazadeh SH, Naghdi BH, Noormohammadi GH, Zand E, Qaderi A. J Med Plants. 2011; 10:6–24.

17. Wani SA, Kumar P. Journal of the Saudi Society of Agricultural Science. 2018; 17:97–106.

18. Shailajan S, Menon S, Singh A, Mhatre M, Sayed N. Pharm Methods. 2011; 2:157–160.

19. Moradi kor N, Didarshetaban MB, Pour HRS. Int J Adv Biol Biom Res. 2013; 1:922–931.

20. Akhtar N, Waqas MK, Ahmed M, Saeed T, Murtaza G, Rasool A, Aamir MN, Khan SA, Bhatti NS, Ali A. Trop J Pharm Res. 2010; 9:329–337.

21. Gade J, More S, Bhalerao N. Int J Sci Res Pul. 2015; 5:1–4.

22. Falla TJ, Zhang L. J Drugs Dermatol. 2010; 9:49–54.

23. Subhashini N, Thangathirupathi A, Lavanya N. Int J Pharm Pharm Sci. 2011; 3:96–102.

24. Waqas MK, Akhtar N, Ahmad M, Murtaza G, Khan HM, Iqbal M, Rasul A, Bhatti NS. Acta Pol Pharm. 2010; 67:173–178.

25. Sreeja S, Anju VS, Sreeja S. Indian J Med Res. 2010; 131:814–819.

26. Hadi RS, Kusuma I, Sandra Y. Univ Med. 2014; 33:91–99.

27. Kusuma I, Hadi RS. Univ Med. 2013; 32:3–10.

28. Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, Minor L. Assay Guidance Manual. U.S.A: Eli Lilly & Company and the National Center for Advancing Translational Sciences;2004. p. 1–25.

29. Surazynski A, Jarzabek K, Haczynski J, Laudanski P, Palka J, Wolczynski S. Int J Mol Med. 2003; 12:803–809.

30. Wang C, Rong YH, Ning FG, Zhang GA. Afr J Biotechnol. 2011; 10:2524–2529.